Cardiac Pharmacology: Difference between revisions

Cardiac Pharmacology (view source)

Revision as of 10:51, 27 May 2013

60 bytes added , 27 May 2013

no edit summary

NiloferT

467

edits

@@ Line 368: / Line 368: @@
 |Heart Failure
 |Captopril: 12.5mg 3 times daily
-|ESC Guidelines (European Heart Journal (2012) 33, 2569–2619 doi:10.1093/eurheartj/ehs215):
+|ESC Guidelines (European Heart Journal (2012) 33, 2569–2619
+doi:10.1093/eurheartj/ehs215):
 Post STEMI: Class IA
 ESC and EASD Guidelines (European Heart Journal doi: 10.1093/eurheart/ehl261)
 Diabetic patients: Class IC
@@ Line 399: / Line 400: @@
 |
 |Angiotensin Receptor Blockers
 |Losartan. Candesartan
 |Hypertension
 |Losartan: 50mg once daily
@@ Line 506: / Line 507: @@
 AF (Poorly tolerated): Class IIaC
 AF (Stable flutter): Class IC
 Prophylaxis of SVT during pregnancy: Class IIaB
 |
 |-
 |
@@ Line 743: / Line 744: @@
 |-
 |Lipid-Lowering Drugs	|Statins
-|Simvastatin, Atorvastatin	Primary hyper-cholesterolaemia, combined hyperlipidaemia	Simvastatin: 10-20mg once daily	ESC and EASD Guidelines (European Heart Journal doi: 10.1093/eurheart/ehl261)
+|Simvastatin, Atorvastatin	|Primary hyper-cholesterolaemia, combined hyperlipidaemia	|Simvastatin: 10-20mg once daily	|ESC and EASD Guidelines (European Heart Journal doi: 10.1093/eurheart/ehl261)
 Dyslipidaemia: Class IA
 Low HDL-C: Class IIbB
@@ Line 757: / Line 758: @@
 doi:10.1093/eurheartj/ehs092):
 Hypertension in diabetics: Class IA
-ACS: Class IA	Oedema (2.7%), abdominal pain (5.9%), nausea (5.4%), atrial fibrillation (5.7%), constipation (2.2%), gastritis (4.9%), diabetes mellitus (4.2%), myalgia (3.7%), headache (2.5%), insomnia (4.0%), vertigo (4.5%), bronchitis (6.6%), sinusitis (2.3%), eczema (4.5%), urinary tract infection (3.2%)
+ACS: Class IA
-			Familial hyper-cholesterolaemia	Simvastatin: 40mg once daily	ESC and EASD Guidelines (European Heart Journal doi: 10.1093/eurheart/ehl261)
+|Oedema (2.7%), abdominal pain (5.9%), nausea (5.4%), atrial fibrillation (5.7%), constipation (2.2%), gastritis (4.9%), diabetes mellitus (4.2%), myalgia (3.7%), headache (2.5%), insomnia (4.0%), vertigo (4.5%), bronchitis (6.6%), sinusitis (2.3%), eczema (4.5%), urinary tract infection (3.2%)
-HeFH: Class IC
+|-
-			Prevention of cardiovascular events	20-40mg once daily	ESC and EASD Guidelines (European Heart Journal doi: 10.1093/eurheart/ehl261):
+|
-Class IA
+|
-	Fibrates	Gemfibrozil	Hyperlipidaemias of types IIa, IIb, III, IV and V 	Gemfibrozil: 0.9-1.2mg daily	ESC and EAS Guidelines (European Heart Journal (2011) 32, 1769–1818
+|
+|Familial hyper-cholesterolaemia	|Simvastatin: 40mg once daily	|ESC and EASD Guidelines (European Heart Journal doi: 10.1093/eurheart/ehl261)
+HeFH: Class IC
+|
+|-
+|
+|
+|
+|Prevention of cardiovascular events
+|20-40mg once daily
+|ESC and EASD Guidelines (European Heart Journal doi: 10.1093/eurheart/ehl261):
+Class IA
+|
+|-
+|
+|Fibrates
+|Gemfibrozil	|Hyperlipidaemias of types IIa, IIb, III, IV and V
+|Gemfibrozil: 0.9-1.2mg daily
+|ESC and EAS Guidelines (European Heart Journal (2011) 32, 1769–1818
 doi:10.1093/eurheartj/ehr158)
 Low HDL-C: Class IIbB
-Transplant patients (with HTG, low HDL-C): Class IIbC	gastro-intestinal disturbances including dyspepsia (19.6%), nausea (4%), abdominal pain (9.8%), diarrhoea (7.2%), vomiting (1.2%); headache (1.2%), fatigue (3.8%), vertigo (1.5%), eczema, rash (1.7%), atrial fibrillation (0.7%), pancreatitis, appendicitis, disturbances in liver function including hepatitis and cholestatic jaundice, dizziness, paraesthesia, sexual dysfunction, thrombocytopenia, anaemia, leucopenia, eosinophilia, bone-marrow suppression, myalgia, myopathy, myasthenia, myositis accompanied by increase in creatine kinase, blurred vision, exfoliative dermatitis, alopecia, and photosensitivity
+Transplant patients (with HTG, low HDL-C): Class IIbC
-	-	Ezetimibe	Primary and familial hyper-cholesterolaemia	10mg once daily	ESC and EAS Guidelines (European Heart Journal (2011) 32, 1769–1818
+|Gastro-intestinal disturbances including dyspepsia (19.6%), nausea (4%), abdominal pain (9.8%), diarrhoea (7.2%), vomiting (1.2%); headache (1.2%), fatigue (3.8%), vertigo (1.5%), eczema, rash (1.7%), atrial fibrillation (0.7%), pancreatitis, appendicitis, disturbances in liver function including hepatitis and cholestatic jaundice, dizziness, paraesthesia, sexual dysfunction, thrombocytopenia, anaemia, leucopenia, eosinophilia, bone-marrow suppression, myalgia, myopathy, myasthenia, myositis accompanied by increase in creatine kinase, blurred vision, exfoliative dermatitis, alopecia, and photosensitivity
+|-
+|
+|
+|Ezetimibe
+|Primary and familial hyper-cholesterolaemia
+|10mg once daily
+|ESC and EAS Guidelines (European Heart Journal (2011) 32, 1769–1818
 doi:10.1093/eurheartj/ehr158)
-Transplant patients (with high LDL-C): Class IIbC	gastro-intestinal disturbance including diarrhoea (4.1%) and abdominal pain (3.0%); headache, fatigue (2.4%); myalgia, arthralgia (3.0%), sinusitis (3.6%), pharyngitis (2.3%), viral infection (2.2%), coughing (2.3%), hypersensitivity reactions including rash, angioedema, and anaphylaxis, hepatitis,pancreatitis, cholelithiasis, cholecystitis, thrombocytopenia, raised creatine kinase, myopathy, and rhabdomyolysis
+Transplant patients (with high LDL-C): Class IIbC
+|Gastro-intestinal disturbance including diarrhoea (4.1%) and abdominal pain (3.0%); headache, fatigue (2.4%); myalgia, arthralgia (3.0%), sinusitis (3.6%), pharyngitis (2.3%), viral infection (2.2%), coughing (2.3%), hypersensitivity reactions including rash, angioedema, and anaphylaxis, hepatitis,pancreatitis, cholelithiasis, cholecystitis, thrombocytopenia, raised creatine kinase, myopathy, and rhabdomyolysis
+|
+|}